Farcnik KD

References (1)

Title : Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications - Baladi_2000_Clin.Ther_22_1549
Author(s) : Baladi JF , Bailey PA , Black S , Bouchard RW , Farcnik KD , Gauthier S , Kertesz A , Mohr E , Robillard A
Ref : Clin Ther , 22 :1549 , 2000
Abstract : Baladi_2000_Clin.Ther_22_1549
ESTHER : Baladi_2000_Clin.Ther_22_1549
PubMedSearch : Baladi_2000_Clin.Ther_22_1549
PubMedID: 11192146